Expert Review of Anticancer Therapy 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
CONCLUSIONS: NTRK-fusion positive tumors are rare but detection is improved through RNA sequencing. TRKi could be considered at diagnosis for CNS NTRK-fusion positive tumors, some IFS and Other-MT.TRIAL REGISTRATION: not adapted.PMID:37434345 | DOI:10.1080/14737140.2023.2236305 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 12, 2023 Category: Cancer & Oncology Authors: Lauriane Lemelle Delphine Guillemot Anne-Laure Hermann Arnaud Gauthier Matthieu Carton Nad ège Corradini Ang élique Rome Pablo Berlanga Anne Jourdain Aude Marie Cardine Sarah Jannier H élène Boutroux Anne Sophie Defachelles Isabelle Aerts Birgit Geoer Source Type: research
Elranatamab: a new promising BispAb in multiple myeloma treatment
Expert Rev Anticancer Ther. 2023 Jul 11. doi: 10.1080/14737140.2023.2236303. Online ahead of print.ABSTRACTINTRODUCTION: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment in collaboration with various cell lineage subsets and growth factors without any perfect regulation and tendency to clonal heterogeneity. Despite remarkable improvement in MM treatment and the overall survival of patients, multiple myeloma remains an incurable disease with the tendency to relapse. Therefore, there is an urgent need for new therapeutic options to provide a stabilized response ...
Source: Expert Review of Anticancer Therapy - July 12, 2023 Category: Cancer & Oncology Authors: Karolina Kociszewska Martyna Bednarczyk Sebastian Grosicki Source Type: research
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
CONCLUSIONS: NTRK-fusion positive tumors are rare but detection is improved through RNA sequencing. TRKi could be considered at diagnosis for CNS NTRK-fusion positive tumors, some IFS and Other-MT.TRIAL REGISTRATION: not adapted.PMID:37434345 | DOI:10.1080/14737140.2023.2236305 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 12, 2023 Category: Cancer & Oncology Authors: Lauriane Lemelle Delphine Guillemot Anne-Laure Hermann Arnaud Gauthier Matthieu Carton Nad ège Corradini Ang élique Rome Pablo Berlanga Anne Jourdain Aude Marie Cardine Sarah Jannier H élène Boutroux Anne Sophie Defachelles Isabelle Aerts Birgit Geoer Source Type: research
Elranatamab: a new promising BispAb in multiple myeloma treatment
Expert Rev Anticancer Ther. 2023 Jul 11. doi: 10.1080/14737140.2023.2236303. Online ahead of print.ABSTRACTINTRODUCTION: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment in collaboration with various cell lineage subsets and growth factors without any perfect regulation and tendency to clonal heterogeneity. Despite remarkable improvement in MM treatment and the overall survival of patients, multiple myeloma remains an incurable disease with the tendency to relapse. Therefore, there is an urgent need for new therapeutic options to provide a stabilized response ...
Source: Expert Review of Anticancer Therapy - July 12, 2023 Category: Cancer & Oncology Authors: Karolina Kociszewska Martyna Bednarczyk Sebastian Grosicki Source Type: research
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
CONCLUSIONS: NTRK-fusion positive tumors are rare but detection is improved through RNA sequencing. TRKi could be considered at diagnosis for CNS NTRK-fusion positive tumors, some IFS and Other-MT.TRIAL REGISTRATION: not adapted.PMID:37434345 | DOI:10.1080/14737140.2023.2236305 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 12, 2023 Category: Cancer & Oncology Authors: Lauriane Lemelle Delphine Guillemot Anne-Laure Hermann Arnaud Gauthier Matthieu Carton Nad ège Corradini Ang élique Rome Pablo Berlanga Anne Jourdain Aude Marie Cardine Sarah Jannier H élène Boutroux Anne Sophie Defachelles Isabelle Aerts Birgit Geoer Source Type: research
